The DEA X-waiver, the requirement that physicians complete an 8-hour training and apply for a federal credential before prescribing buprenorphine for opioid use disorder, existed for twenty-three years. It was created in 2000 as part of the Drug Addiction Treatment Act and was understood, by anyone who had spent more than two weeks in the addiction-medicine field, to be an obstacle to good care that was originally written into law because it sounded like a safeguard. It was not a safeguard. It was a tax on the kind of clinician who would already be cautious. It funneled patients with opioid use disorder away from the medical homes they already had and into a small set of waivered providers, most of whom had waitlists, most of whom were located in places that were not where the patients were.
The Mainstreaming Addiction Treatment Act, signed into law in December 2022 as part of the Consolidated Appropriations Act, removed the X-waiver requirement effective the following year. SAMHSA's guidance after the law went live made the operational meaning explicit: any DEA-registered prescriber may prescribe buprenorphine for OUD, subject to the standard DEA registration and Schedule III rules. The 8-hour training is no longer required for the prescription. (A separate 8-hour training requirement was added to DEA registration renewal under the MATE Act, which is a different rule and which we will not relitigate here.)[01]
The right reading of this law is that it removed an obstacle. It did not create capacity. The capacity has to be created by the practices that decide to take it on.
What we changed at the front desk
The first change was a one-page front-desk script for any inquiry that mentioned buprenorphine, methadone, opioid use disorder, addiction, or "Suboxone." The script is twelve questions long. The script is not optional. The script is read in the order it is written, and the answers are entered into a structured intake template before any clinical decision is made.
The questions are, in summary:
- Who is calling? (Self, family member, referring clinician.)
- Is the patient currently using opioids? (If yes, what, how often, last use.)
- Has the patient been on buprenorphine before? (If yes, where, with whom, when last dose, why stopped.)
- Is the patient currently on methadone? (Routing question — methadone for OUD is an OTP service.)
- Is the patient experiencing acute withdrawal now? (Routing question — same-day vs scheduled.)
- Is the patient pregnant? (Routing — co-management with OB at MidHudson.)
- Does the patient have insurance? (Coverage check.)
- What pharmacy does the patient use? (Coordination.)
- Has the patient ever been hospitalized for withdrawal, overdose, or related conditions? (Risk stratification.)
- Does the patient have a current naloxone prescription? (We will write one.)
- Is the patient willing to come in for an in-person evaluation? (Some patients want telehealth; we are flexible per SAMHSA telehealth guidance; the in-person preference is documented.)
- Does the patient prefer to start at home or in the office?
The script was written by Maren Vanderlyn and me on the Sunday after the rule went live. We tested it on Monday. We modified question 9 on Tuesday after the front-desk found that "ever" was producing too many false positives; we now ask "in the last three years."
How we changed the workflow
Before the rule change, the X-waiver requirement had limited buprenorphine prescribing at this practice to me. I held the panel because I was the only waivered clinician. After the rule change, all five of our DEA-registered prescribers were eligible to prescribe; in practice, Maren Vanderlyn and Tessa Voorhies have taken on a small number of OUD patients each, and Salim Okonkwo, who is also DEA-registered, prescribes for the patients who are primarily in the BH panel. We do not advertise this distribution; from the patient's perspective the question of "who is your buprenorphine prescriber" is the same as "who is your primary clinician at this practice."
The induction protocol — the practical question of how to get from the call to the first dose — is now described in CCH-003 § Mechanism. We use SAMHSA TIP-63 as the reference. We offer both home and office induction; office induction is on Tuesday and Thursday afternoons because that is when I am here. Home induction is more common in our panel.
What the deregulation did not change
The MAT Act removed the X-waiver. It did not change: the DEA Schedule III rules; the requirement to query the NY PMP before prescribing; the methadone-for-OUD rules (still OTP-only); the practical reality that the patient still has to fill the prescription, get to the appointment, and remain in care. None of those is solved by federal law.
The deregulation also did not change the local clinical capacity. The most-cited paper on this remains Olfson et al., 2023, which reports modest increases in buprenorphine prescribing and no change in overdose mortality through the first year after the rule change.[02] The capacity has to be built. The X-waiver was a barrier, but barriers are not the same as buildings.
What the patient should expect
If you call the front desk about buprenorphine: you will be asked the twelve questions above. You will be offered an evaluation visit within one business day for active withdrawal, within five business days for scheduled care. We will write a naloxone prescription with every buprenorphine prescription unless you tell us not to. We will not require you to "fail" some other treatment first; the medication is not a punishment. We will ask you to consent to a urine drug screen at intake and at intervals discussed at induction.
References
- SAMHSA, Removal of DATA Waiver (X-Waiver) Requirement, 2023 — samhsa.gov.
- Olfson M et al., Buprenorphine treatment after the elimination of the X-waiver, JAMA Network Open 2023 — jamanetwork.com.
- SAMHSA TIP-63: Medications for Opioid Use Disorder — store.samhsa.gov.
- Provider Clinical Support System — pcssnow.org.
- NY State Prescription Monitoring Program — health.ny.gov.
- FDA Information about Medications for Opioid Use Disorder (MOUD) — fda.gov.
- SAMHSA buprenorphine-with-telehealth guidance — samhsa.gov.